Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 4 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready
Lycia Therapeutics Inc. has 4 pending office actions in the Biotechnology & Pharmaceuticals technology area. These matters are distributed among 4 distinct examiners and 4 distinct art units, showing a one-to-one relationship between actions and reviewers. GALSTER, SAMUEL LEONARD is the busiest examiner, currently handling 1 pending office action.
With 4 pending office actions in total, the company must manage four separate prosecution tracks. This distribution across 4 distinct art units suggests a diverse range of therapeutic technologies under review.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 3 (75%) |
| Multi-statute (no §101) | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GALSTER, SAMUEL LEONARD | 1 | 52.1% | +42.2% |
| REDWOOD, CHRISTOPHER EVAN | 1 | 0.0% | +0.0% |
| BERTOGLIO, VALARIE E | 1 | 64.1% | +30.3% |
| JADHAO, SAMADHAN JAISING | 1 | 46.2% | +47.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18271230 | Bifunctional Folate Receptor Binding Compounds | REDWOOD, CHRISTOPHER EVAN | — |
| 18012838 | MODIFIED VIRAL COMPOSITIONS FOR VIRAL TRANSDUCTION | JADHAO, SAMADHAN JAISING | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18012840 | BIFUNCTIONAL BRIDGING COMPOSITIONS FOR VIRAL TRANSDUCTION | BERTOGLIO, VALARIE E | 7d |
| 18578293 | M6PR CELL SURFACE RECEPTOR BINDING COMPOUNDS AND CONJUGATES | GALSTER, SAMUEL LEONARD | — |
| 18012838 | MODIFIED VIRAL COMPOSITIONS FOR VIRAL TRANSDUCTION | JADHAO, SAMADHAN JAISING | — |
| Art Unit | Apps |
|---|---|
| 1693 | 1 |
| 1629 | 1 |
| 1632 | 1 |
| 1672 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18578293 | M6PR CELL SURFACE RECEPTOR BINDING COMPOUNDS AND CONJUGATES | GALSTER, SAMUEL LEONARD | 1693 | §102§103§112DP | Non-Final OA | — | Pending | Jan 10, 2024 |
| 18271230 | Bifunctional Folate Receptor Binding Compounds | REDWOOD, CHRISTOPHER EVAN | 1629 | §102§103§112DP | Non-Final OA | — | Pending | Jul 06, 2023 |
| 18012840 | BIFUNCTIONAL BRIDGING COMPOSITIONS FOR VIRAL TRANSDUCTION | BERTOGLIO, VALARIE E | 1632 | §103DP | Non-Final OA | 7d | Pending | Dec 23, 2022 |
| 18012838 | MODIFIED VIRAL COMPOSITIONS FOR VIRAL TRANSDUCTION | JADHAO, SAMADHAN JAISING | 1672 | §102§103§112 | Final Rejection | — | Pending | Dec 23, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialLycia Therapeutics Inc. has 4 pending office actions as of October 2026, spread across 4 art units and 4 examiners.
Samuel Leonard Galster has the most, with 1 of Lycia Therapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
